Clinical characteristics and response to tyrosine kinase inhibitors of patients with non-small cell lung cancer harboring uncommon epidermal growth factor receptor mutations

Documenti analoghi

• Tyrosine Kinase Inhibitors Could Be Effective Against Non-small Cell Lung Cancer Brain Metastases Harboring Uncommon EGFR Mutations
  di: Ma, Chunhua, et al.
  Pubblicazione: (2020)
• Effectiveness of tyrosine kinase inhibitors on uncommon E709X epidermal growth factor receptor mutations in non-small-cell lung cancer
  di: Wu, Jenn-Yu, et al.
  Pubblicazione: (2016)
• Efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors for Chinese patients with squamous cell carcinoma of lung harboring EGFR mutation
  di: Fang, Wenfeng, et al.
  Pubblicazione: (2013)
• Next-generation sequencing of tyrosine kinase inhibitor-resistant non-small-cell lung cancers in patients harboring epidermal growth factor-activating mutations
  di: Masago, Katsuhiro, et al.
  Pubblicazione: (2015)
• The Efficacy and Safety of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Combined With Thymosin in Advanced Non-Small Cell Lung Cancer Patients Harboring Active Epidermal Growth Factor Receptor Mutations
  di: Feng, Yongdong, et al.
  Pubblicazione: (2021)